Literature DB >> 26756999

A Cross-Sectional Cohort Study of Cerebrovascular Disease and Late Effects After Radiation Therapy for Craniopharyngioma.

Andrea C Lo1,2, A Fuchsia Howard3, Alan Nichol1,2, Haroon Hasan1, Monty Martin2,4, Manraj Heran2,5, Karen Goddard1,2.   

Abstract

BACKGROUND: The study objective was to describe radiation-induced vascular abnormalities, stroke prevalence, and stroke risk factors in survivors of childhood craniopharyngioma. PROCEDURE: Twenty survivors of childhood craniopharyngioma who received radiotherapy (RT) were included in the study. A clinical history, quality of life assessment, cognitive functioning assessment, magnetic resonance angiogram or computed tomography angiogram, fasting lipid profile, and fasting glucose or hemoglobin A1c test were obtained.
RESULTS: Median age at diagnosis was 10.3 years and median age at time of study was 29.0 years. Vascular abnormalities were detected in six (32%) of 19 patients' angiograms (vascular stenosis, decreased artery size, aneurysm, cavernoma, and small vessel disease). Five (25%) of 20 patients experienced a stroke after RT. Median time since RT was 27.8 versus 9.1 years in patients with versus without vascular abnormalities (P = 0.02). A low level of high-density lipoproteiin (HDL) was present in 100% (5/5) of patients who had a post-RT stroke as compared with 13% (2/15) of patients who did not have any post-RT stroke (P = 0.02). Previous stroke had occurred in 0% (0/5) of patients receiving growth hormone (GH) replacement at the time of study, compared to 40% (6/15) of patients who were not receiving GH replacement (P = 0.09).
CONCLUSIONS: Patients with craniopharyngioma treated with RT have a high prevalence of stroke and vascular abnormalities, particularly those with low HDL and longer duration of time since RT. There is a trend to suggest that continual GH replacement may reduce the risk of stroke. These patients should undergo careful monitoring and aggressive modification of stroke risk factors.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cerebrovascular accident; craniopharyngioma; late effects; radiation therapy; stroke

Mesh:

Year:  2016        PMID: 26756999     DOI: 10.1002/pbc.25889

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

Review 1.  Microsurgical removal of craniopharyngioma: endoscopic and transcranial techniques for complication avoidance.

Authors:  Saira Alli; Semra Isik; James T Rutka
Journal:  J Neurooncol       Date:  2016-05-19       Impact factor: 4.130

Review 2.  Systematic review of the incidence and risk factors for cerebral vasculopathy and stroke after cranial proton and photon radiation for childhood brain tumors.

Authors:  Abhishek Bavle; Anand Srinivasan; Farooq Choudhry; Michael Anderson; Michael Confer; Hilarie Simpson; Theresa Gavula; J Spencer Thompson; Shari Clifton; Naina L Gross; Rene McNall-Knapp
Journal:  Neurooncol Pract       Date:  2020-09-28

3.  Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma: Expressions of vascular endothelial growth factor and its receptor-2 and imaging features of tumors are associated with tumor radiosensitivity.

Authors:  Chenhao Hu; Jinhui Chen; Yuhong Meng; Jianning Zhang; Yaming Wang; Rui Liu; Xin Yu
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

4.  Increased risk of cerebrovascular mortality in head and neck cancer survivors aged ≥ 65 years treated with definitive radiotherapy: a population-based cohort study.

Authors:  Qing-Song He; Zhen-Ping Wang; Zhao-Jun Li; Ping Zhou; Chen-Lu Lian; San-Gang Wu; Si-Fang Chen
Journal:  Radiat Oncol       Date:  2021-09-20       Impact factor: 3.481

Review 5.  Giant intracranial aneurysm following radiation therapy: literature review with a novel case discussion.

Authors:  Aldo Paolucci; Luigi Schisano; Mauro Pluderi; Nadia Grimoldi; Ferdinando Caranci; Alessio Angileri; Antonio Arrichiello; Antonella Costa
Journal:  Acta Biomed       Date:  2020-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.